↓ Skip to main content

Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression

Overview of attention for article published in Breast Cancer Research, April 2013
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
18 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression
Published in
Breast Cancer Research, April 2013
DOI 10.1186/bcr3406
Pubmed ID
Authors

Swarnali Acharyya

Abstract

HER2 amplification and overexpression is observed in approximately 20% of breast cancers and is strongly associated with poor prognosis and therapeutic responsiveness to HER2 targeted agents. A recent study by Bose and colleagues suggests that another subset of breast cancer patients without HER2 amplification but with activating HER2 mutation might also benefit from existing HER2-targeted agents and the authors functionally characterize these somatic mutations in experimental models. In a second study on HER2-driven breast cancer, Angelini and colleagues investigate how the constitutively active, truncated carboxy-terminal fragment of HER2, p95HER2, promotes metastatic progression through non-cellautonomous secretion of factors from senescent cells. These new findings advance our understanding of HER2 biology in the context of HER2 activation as well as offer new insights into our understanding of drug sensitivity and metastatic progression.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 6%
Unknown 17 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 28%
Researcher 3 17%
Other 2 11%
Student > Bachelor 1 6%
Lecturer 1 6%
Other 2 11%
Unknown 4 22%
Readers by discipline Count As %
Medicine and Dentistry 6 33%
Biochemistry, Genetics and Molecular Biology 4 22%
Agricultural and Biological Sciences 2 11%
Psychology 1 6%
Nursing and Health Professions 1 6%
Other 0 0%
Unknown 4 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 April 2013.
All research outputs
#20,656,161
of 25,373,627 outputs
Outputs from Breast Cancer Research
#1,705
of 2,052 outputs
Outputs of similar age
#158,182
of 207,222 outputs
Outputs of similar age from Breast Cancer Research
#26
of 28 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,052 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,222 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.